WO1990001063A1 - New secretory leader sequences - Google Patents
New secretory leader sequences Download PDFInfo
- Publication number
- WO1990001063A1 WO1990001063A1 PCT/GB1989/000816 GB8900816W WO9001063A1 WO 1990001063 A1 WO1990001063 A1 WO 1990001063A1 GB 8900816 W GB8900816 W GB 8900816W WO 9001063 A1 WO9001063 A1 WO 9001063A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ser
- leu
- phe
- sequence
- arg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
Definitions
- This invention relates to secretory leader sequences which can be employed to direct the secretion of a heterologous protein (such as human serum albumin) from fungi (for example the yeast Saccharomyces eerevisiae) .
- a heterologous protein such as human serum albumin
- fungi for example the yeast Saccharomyces eerevisiae
- leader sequence is usually essential for the translocation of proteins across membranes
- these sequences are usually endoproteo- lytically cleaved by enzymes contained within the cellular compartments into which the proteins have now moved. These enzymes recognise specific amino acid sequences within the primary structure of the translocated protein.
- complete processing of certain eukaryotic proteins to their mature form often relies upon a series of proteolytic cleavages (Bussey, H., 1988 Yeast 4_, 17-26).
- yeast secretory sequence is the 89 amino acid leader sequence of the alpha-factor mating pheromone. Processing of this leader has been extensively studied ( urjan & Herskowitz, Cell 30_, 933-943, 1982; Julius et al. 1983 Cell _3_2, 839-852; Dmochowska* et al. Cell 5_0_, 573-584, 1987; Julius et al. Cell 3_6: 309-318, 1984; Julius et al. Cell 3 1075-1085, 1984) and requires at least four gene products for complete proteolytic cleavage to liberate the mature 13 amino acid alpha-factor pheromone.
- KE 2 gene product an endopeptidase which cleaves after the Lys-Arg dibasic amino acid pair, a carboxypeptidase ⁇ -like cleavage, recently identified as the product of the KEXl gene, and a dipeptidyl amino peptidase, the product of the STE13 gene, which sequentially removes the Glu-Ala or Asp-Ala diamino acid pairing preceding the mature alpha-factor pheromone.
- the alpha factor prepro leader sequence has successfully been employed to secrete a range of diverse proteins and peptides. However, when the alpha-factor signal is used to direct secretion of human serum albumin, we have found that a large proportion of the extracellular HSA produced is in the form of a 45KD N-terminal fragment.
- EP-A-252 561 discloses the use of the 16 amino acid signal peptide (pre-sequence) from the killer toxin of Kluyveromyces lactis to aid secretion of heterologous proteins in yeast.
- BSTITUTESHEET A further possibility is to use a fusion secretory leader sequence. This may be generated by the fusion of two independent sequences.
- a hybrid signal in which the first amino acids of the acid phosphatase signal were fused to the proteolytic cleavage site of human alpha interferon resulted in the expression and secretion of interferon (Hinnen et a_l. Foundation for Biochemical and Industrial Fermentation Research, 229, 1219-1224, 1983); 10% of the interferon produced was secreted into the medium.
- a fusion leader comprising the first 9 amino acids of the chicken lysozyme leader and the last 9 amino acids of the Aspergillus awamori glycoamylase leader.
- this fusion leader was effective in secreting 60% of the produced material into the culture supernatant, it was only 15% as effective as the entire chicken lysozyme leader.
- no secreted product could be detected if the human lysozyme sequences were preceded by the entire Aspergillus glycoamylase leader, or a fusion derived from the first 9 amino acids of the Aspergillus glucoamylase leader and the last 9 amino acids of the chicken lysozyme leader.
- One aspect of the invention provides an amino acid sequence as follows:
- Table 1 shows alternative amino acids for each position except the initial methionine. Any of the possible permutations are within the scope of the invention.
- the selection of lysine or arginine for the last two positions is particularly non-critical, although there should always be Lys or Arg at each of these positions.
- positions 20 and 21 of sequence (a) are not Gly and Val respectively.
- Sequences which are up to four amino acids shorter or longer are also included provided that the C-terminal (Lys, Arg), Lys-Lys or Arg-Arg entity is maintained, there is a positively charged residue within 5 residues of the N-terminus and there is a generally hydrophobic region at or adjacent the middle of the sequence.
- Trp lie lie Thr Trp Leu
- a second aspect provides a fusion compound comprising any of the said amino acid sequences linked, preferably directly, at the carboxyl terminal to the N- terminal residue of a polypeptide.
- the polypeptide may be any desired polypeptide, including "pro-polypeptides" (in other words precursors which undergo post-translational cleavage or other modification, such as glycosylation) .
- the term "polypeptide” encompasses oligopeptides.
- the polypeptide may be fibronectin or a portion thereof (for example the collagen or fibrin-binding portions described in EP 207 751), urokinase, pro-urokinase, the 1-368 portion of CD4 (D.
- the polypeptide may also be a fusion of HSA or an N-terminal portion thereof and any other polypeptide, such as those listed above.
- the polypeptide is a naturally-occurring human serum albumin, a modified human serum albumin or a fragment of either, such modified forms and fragments being termed "variants".
- variants include all forms or fragments of HSA which fulfill at least one of the physiological functions of HSA and which are sufficiently similar to HSA, in terms of structure (particularly tertiary structure) as to be regarded by the skilled man as forms or fragments of HSA.
- HSA which retain at least 50% of its ligand-binding properties, for example with respect to bilirubin or fatty acids, (preferably 80%, or 95%) are encompassed.
- ligand-binding properties for example with respect to bilirubin or fatty acids, (preferably 80%, or 95%) are encompassed.
- Such properties are discussed in Brown, J.R. & Shockley, P. (1982) in Lipid-Protein Interactions .1, 26-68, Ed. Jost, P.C. & Griffith, O.H.
- the portion of HSA disclosed in EP 322 094 is an example of a useful fragment of HSA which may be secreted by use of the leader sequences of the invention.
- a third aspect provides a nucleotide sequence coding for any of the said amino acid sequences or for the said fusion compound.
- the nucleotide sequence (or the portion thereof encoding the leader sequence) may be selected from the possibilities shown in Tables 2 & 3, for sequences (a) and (b) respectively, where the codons encoding each amino acid are listed under the amino acids.
- the codons of Tables 2 and 3 clearly relate to RNA, but it is to be understood that equivalent DNA nucleotide sequences are also within the scope of this aspect of the invention.
- AGU AGU CUA CUA CUA .
- AGU AGU
- a fourth aspect provides a DNA construct comprising a suitable control region or regions and a nucleotide sequence as defined above, the sequence being under the control of the control region.
- suitable control region we mean such DNA regions as are necessary to enable the said nucleotide sequence to be expressed in the host for which the construct is intended.
- the control region will usually include transcriptional start and
- SUBSTITUTE SHEET stop sequences 3'-polyadenylation sequences, a promoter and, often, an upstream activation site for the promoter.
- suitable expression vectors and their construction include those disclosed in EP 198 745, GB 2 171 703 (for B.subtilis), EP 207 165, EP 116 201, EP 123 244, EP 123 544, EP 147 198, EP 201 239, EP 248 637, EP 251 744, EP 258 067, EP 286 424 and EP 322 094.
- a fifth aspect provides a host transformed with the said DNA construct.
- the host may be any host in which the construct is found to work adequately, including bacteria, yeasts, filamentous fungi, insect cells, plant cells and animal cells.
- the host is Saccharomyces eerevisiae or Schizosaccharomyces pombe, most preferably the former.
- native secretion signals are effective in heterologous hosts (for example the natural HSA leader sequence in yeast) it is entirely reasonable to suppose that the leader sequences of the invention will function in hosts other than yeasts.
- a sixth aspect provides a process for preparing a polypeptide, comprising cultivating the said host and obtaining therefrom the polypeptide expressed by the said nucleotide sequence, or a modified version thereof.
- modified version thereof we mean that the actual polypeptide which is separated may have been post- translationally modified, in particular by cleavage of the leader sequence.
- a seventh aspect provides a polypeptide prepared by such a process.
- Figure 1 is a restriction map of plasmid pEKH3
- Figure 2 is a restriction map of plasmid pEK25
- Figure 3 is a restriction map of plasmid pAYE230
- Figure 4 is a restriction map of plasmid pAYE238
- Figure 5 is a restriction map of plasmid pAYE305
- Figure 6 is a restriction map of plasmid pAYE305.
- the DNA coding sequence for mature HSA protein has been placed immediately downstream of a DNA sequence encoding the KEX2 cleavage site of the alpha factor pre pro leader sequence (85 amino acids).
- this protein sequence is placed under the control of a promoter on a yeast autonomously replicating plasmid and transformed into a haploid strain of the yeast Saccharomyces eerevisiae, mature HSA can be detected in the culture supernatant.
- N-terminal amino acid sequence information indicates that the secreted protein has the same N- terminal amino acid composition as natural HSA, namely Asp-Ala-His.
- fusion leader which may be regarded as the natural HSA leader sequence from which the last five amino acids have been removed, to be replaced by the five amino acids preceding the KEX2 cleavage site of the alpha-factor pre pro leader sequence, i.e. amino acids 81 to 85 are Ser-Leu-Asp-Lys- Arg (Table 2) .
- yeast When transformed with suitable plasmid vectors incorporating the fusion leader, yeast secrete mature HSA into the culture supernatant at levels comparable to that observed with the alpha-factor leader sequence. N- terminal sequence analysis indicates that the mature HSA possesses the correct N-terminal amino acid composition.
- substitution of the alpha-factor leader by the fusion leader sequence has been found to result in a 6 fold reduction in the levels of the 45 kd fragment observed in the culture supernatant. This therefore represents a significant improvement in the reduction of the contaminating polypeptides, thus aiding the purification of mature HSA from yeast culture supernatants.
- Plasmid pEK113 ( Figure 1) (EP-A-248 637) was digested to completion with the restriction endonucleases Mstll and HindiII. DNA was recovered by phenol/chloroform extraction and ethanol precipitation. The linearised plasmid DNA was then treated with the Klenow fragment of E.coli DNA polymerase I to generate a linearised DNA molecule with blunt ends.
- oligonucleotide duplex (I) was constructed on an automated Applied Biosystems Inc 38OB DNA synthesiser (according to manufacturer's instructions) .
- the oligonucleotide duplex was ligated with equimolar quantities of linearised, blunt ended pEKH3.
- E.coli strain MC1061 was transformed with the ligation mixture and cells receiving DNA were selected on an ampicillin-containing medium (50ug/ml ampicillin) .
- Recombinant plasmids containing the oligonucleotide duplex were screened by digesting DNA prepared from individual colonies with the restriction endonucleases Mstll and EcoRI. Plasmid pEK25 was thus formed ( Figure 2).
- Plasmid pEK25 was digested to completion with the restriction endonucleases Xbal and BamHI, DNA fragments were separated by electrophoresis through a 1% (w/v) agarose gel and a 688 base pair Xbal - BamHI DNA fragment recovered from the gel by electroelution.
- the plasmid mpl9.7 (EP-A-248 637) was digested to completion with the restriction endonuclease Xhol.
- the linearised DNA was phenol/chloroform extracted and ethanol precipitated.
- the recovered DNA was then treated with the Klenow fragment of E. coli DNA polymerase I as previously described, following which the DNA was phenol/chloroform extracted and ethanol precipitated.
- the recovered DNA was then digested to completion with Xbal and the digestion products separated by agarose gel electrophoresis. A 1067 base pair fragment was recovered from the gel by electroelution.
- the following oligo ⁇ nucleotide duplex (II) was prepared as described previously. Oligonucleotide II
- the plasmid pUC19 (Yanisch-Perron et al. 1985) was digested to completion with the restriction endonuclease BamHI. Linearised DNA was recovered by phenol/chloroform extraction and ethanol precipitation.
- Equimolar quantities of the BamHI digested pUC19, the oligonucleotide duplex II, the 1067 b.p. DNA fragment derived from mpl9.7 and the 688 b.p. DNA fragment derived from pEK25 were ligated together.
- E.coli DH5 was trans ⁇ formed with the ligated DNA and transformants selected on 50ug/ml ampicillin L-broth agar.
- Recombinant colonies containing the desired plasmid, designated pAYE 230 ( Figure 3) were selected by digested DNA obtained from individual colonies with the restriction endonuclease BamHI.
- Plasmid pAYE 230 was digested to completion with BamHI and the products separated by electrophoresis through a 1% agarose gel. The 1832 base pair fragment containing the HSA coding sequence was recovered by electroelution.
- Plasmid pMA91 (Mellor et a_l. 1983) was digested to completion with Bglll under standard conditions. The linearised plasmid was phenol/chloroform extracted and ethanol precipitated.
- Plasmid pAYE 238 was transformed into the yeast Saccharomyces eerevisiae strain S150-2B as described by Hinnen et al. (1978). Cells receiving plasmid pAYE 238 were selected on minimal medium, supplemented with 2% (w/v) glucose, 20mg/l histidine, 20mg/l tryptophan and 20mg/l uracil. Transformed S150-2B cells were transferred to 10ml YEPD media containing 2% (w/v) glucose and incubated at 30°C, 200rpm for 72 hours.
- a second fusion leader which consists of the 16 amino acid pre region of the 97,000 dalton Kluyveromyces lactis killer (ORF 2) toxin (Stark and Boyd, 1986, Tokumaga efc al 1987) fused to the five amino acids preceding the KE 2 cleavage site of the alpha-factor prepro leader sequence, i.e. amino acids 81 to 85, Ser-Leu-Asp-Lys-Arg (Table 3).
- Equimolar quantities of the BamHI digested pUC19, the oligonucleotide duplex III, the 1067bp DNA fragment derived from mpl9.7 and the 688b.p. DNA fragment derived from pEK25 were ligated together.
- E.coli DH5 was transformed with ligated DNA and transformants selected on 50 ⁇ g/ml ampicillin L-broth agar. Recombinant colonies containing the desired plasmid, designated pAYE304 ( Figure 5), were selected by digested DNA obtained from individual colonies with the restriction endonuclease BamHI.
- Plasmid pAYE304 was digested to completion with BamHI and the products separated by electrophoresis through a 1% agarose gel. The 1823 base pair fragment containing the HSA coding sequence was recovered by electroelution.
- Plasmid pMA91 (Mellor et al, 1983) was digested to completion with Bglll under standard conditions. The linearised plasmid was phenol/chloroform extracted and ethanol precipitated.
- E.coli DH5 was transformed with the ligation mixture and cells receiving DNA selected on L- broth agar containing 50 ⁇ g/ml ampicillin. Colonies containing the desired plasmid, designating pAYE305 ( Figure 6), were selected by digesting the DNA from such colonies with PvuII.
- Plasmid pAYE305 was transformed into the yeast Saccharomyces eerevisiae strain S150-2B as described by Hinnen et aJL, (1978). Cells receiving plasmid pAYE305 were selected on minimal medium, supplemented with 2% (w/v) glucose, 20mg/l histidine, 20mg/l tryptophan and 20mg/l uracil.
- Transformed S150-2B cells were transferred to 10ml YEPD medium containing 2% (w/v) glucose and incubated at 30°C, 200rpm for 72 hours.
- Cell free culture supernatants were analysed by discontinuous native 8-25% gradient polyacrylamide gel electrophoresis on a Pharmacia Phast System, as described in the manufacturer's instructions.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019900700595A KR100195632B1 (en) | 1988-07-23 | 1989-07-14 | New secretory leader sequences |
EP89909015A EP0387319B1 (en) | 1988-07-23 | 1989-07-14 | Secretory leader sequences |
DE68925893T DE68925893T2 (en) | 1988-07-23 | 1989-07-14 | SECRETORIC LEADER SEQUENCES |
GB8928849A GB2230268B (en) | 1988-07-23 | 1989-12-21 | Leader sequences for the secretion of heterologous polypeptides from fungi. |
FI901428A FI104564B (en) | 1988-07-23 | 1990-03-21 | Peptide and DNA sequences |
DK199000729A DK175853B1 (en) | 1988-07-23 | 1990-03-21 | Secretory leader sequences |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8817598.9 | 1988-07-23 | ||
GB888817598A GB8817598D0 (en) | 1988-07-23 | 1988-07-23 | Dna & peptide sequences |
GB8906920.7 | 1989-03-28 | ||
GB898906920A GB8906920D0 (en) | 1989-03-28 | 1989-03-28 | Peptide and dna sequences |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990001063A1 true WO1990001063A1 (en) | 1990-02-08 |
Family
ID=26294196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1989/000816 WO1990001063A1 (en) | 1988-07-23 | 1989-07-14 | New secretory leader sequences |
Country Status (15)
Country | Link |
---|---|
US (1) | US5302697A (en) |
EP (1) | EP0387319B1 (en) |
JP (1) | JP3092811B2 (en) |
KR (1) | KR100195632B1 (en) |
AT (1) | ATE135045T1 (en) |
AU (1) | AU633020B2 (en) |
CA (1) | CA1340547C (en) |
DE (1) | DE68925893T2 (en) |
DK (1) | DK175853B1 (en) |
FI (1) | FI104564B (en) |
GB (1) | GB2230268B (en) |
HU (1) | HU213571B (en) |
IE (1) | IE62266B1 (en) |
IL (1) | IL91024A (en) |
WO (1) | WO1990001063A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0366400A2 (en) * | 1988-10-26 | 1990-05-02 | Tonen Corporation | DNA encoding human serum albumin a (HSA), plasmids and hosts containing such DNA, and the production of HSA |
WO1992011378A1 (en) * | 1990-12-19 | 1992-07-09 | Novo Nordisk A/S | A method of constructing synthetic leader sequences |
US5521086A (en) * | 1993-09-16 | 1996-05-28 | Cephalon, Inc. | Secretion sequence for the production of a heterologous protein in yeast |
US5919654A (en) * | 1995-02-03 | 1999-07-06 | Asahi Glass Company Ltd. | Secretion signal gene and expression vector containing it |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2004009819A2 (en) * | 2002-07-23 | 2004-01-29 | Delta Biotechnology Limited | Polypeptides with a signal sequence comprising an fivsi motif and olynucleotides encoding therefor |
US6867231B1 (en) | 1997-06-14 | 2005-03-15 | Enzacta R & D Limited | Therapeutic systems |
US7045318B2 (en) * | 1995-12-30 | 2006-05-16 | Delta Biotechnology Limited | Recombinant fusion proteins to growth hormone and serum albumin |
WO2006067511A1 (en) | 2004-12-23 | 2006-06-29 | Novozymes Delta Limited | Gene expression technique |
WO2009019314A1 (en) | 2007-08-08 | 2009-02-12 | Novozymes A/S | Transferrin variants and conjugates |
EP2048234A1 (en) | 1999-01-30 | 2009-04-15 | Novozymes Biopharma UK Limited | Chromatographic method for purification of albumin |
EP2048236A1 (en) | 2003-12-23 | 2009-04-15 | Novozymes Biopharma DK A/S | Gene expression technique |
EP2090589A1 (en) | 2002-02-07 | 2009-08-19 | Dyax Corp. | Albumin-fused Kunitz domain peptides |
EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2010089385A1 (en) | 2009-02-06 | 2010-08-12 | Novozymes Biopharma Dk A/S | Purification process |
WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
US8252551B2 (en) | 2003-12-23 | 2012-08-28 | Novozymes Biopharma Dk A/S | 2-micron family plasmid and use thereof |
US8420087B2 (en) | 2004-01-05 | 2013-04-16 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
WO2014012082A2 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
US8765915B2 (en) | 2006-02-06 | 2014-07-01 | Csl Behring Gmbh | Modified coagulation factor VIIa with extended half-life |
WO2014182970A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
WO2016086320A1 (en) | 2014-12-05 | 2016-06-09 | UNIVERSITé LAVAL | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
US9499605B2 (en) | 2011-03-03 | 2016-11-22 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
US9505823B2 (en) | 2006-08-07 | 2016-11-29 | TEV A Biopharmaceuticals USA, Inc. | Albumin-insulin fusion proteins |
WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
WO2018234349A1 (en) | 2017-06-20 | 2018-12-27 | Albumedix Ltd | Improved protein expression strains |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340772C (en) | 1987-12-30 | 1999-09-28 | Patricia Tekamp-Olson | Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences |
DK105489D0 (en) * | 1989-03-03 | 1989-03-03 | Novo Nordisk As | POLYPEPTIDE |
US5766883A (en) * | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
FR2650598B1 (en) * | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5712114A (en) * | 1995-06-06 | 1998-01-27 | Basf Aktiengesellschaft | Compositions for expression of proteins in host cells using a preprocollagen signal sequence |
WO1999024075A2 (en) * | 1997-11-07 | 1999-05-20 | Conjuchem, Inc. | Affinity markers for human serum albumin |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050244931A1 (en) * | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
AU2002332041A1 (en) * | 2001-10-05 | 2003-04-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1463752A4 (en) * | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Albumin fusion proteins |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | Albumin fusion proteins |
JP5236189B2 (en) | 2003-12-05 | 2013-07-17 | チルドレンズ ホスピタル メディカル センター | Oligosaccharide composition and use of the composition in the treatment of infectious diseases |
AU2007278994B2 (en) | 2006-07-24 | 2013-08-15 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
US7803769B2 (en) * | 2006-10-25 | 2010-09-28 | Amgen Inc. | OSK1 peptide analogs and pharmaceutical compositions |
WO2008153745A2 (en) | 2007-05-22 | 2008-12-18 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
JP2012521197A (en) | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Carrier immunoglobulin and use thereof |
CA2781532A1 (en) | 2009-11-20 | 2011-05-26 | Amgen Inc. | Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1 |
WO2012021648A1 (en) | 2010-08-10 | 2012-02-16 | Amgen Inc. | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies |
US8993727B2 (en) | 2010-09-22 | 2015-03-31 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
KR20140009311A (en) | 2011-01-18 | 2014-01-22 | 암젠 인크 | Nav1.7 knockout mice and uses thereof |
PE20140593A1 (en) | 2011-03-16 | 2014-05-10 | Amgen Inc | POWERFUL AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 |
EP2816893A1 (en) | 2012-02-22 | 2014-12-31 | Amgen Inc. | Autologous mammalian models derived from induced pluripotent stem cells and related methods |
US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
US11078464B2 (en) | 2013-08-30 | 2021-08-03 | Amgen Inc. | High titer recombinant AAV vector production in adherent and suspension cells |
US10463716B2 (en) | 2014-10-13 | 2019-11-05 | University Of Maryland, Baltimore | Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone |
EP3207146B1 (en) | 2014-10-15 | 2021-09-29 | Amgen Inc. | Promoter and regulatory elements for improved expression of heterologous genes in host cells |
US11028410B2 (en) | 2016-01-27 | 2021-06-08 | Just-Evotec Biologics, Inc. | Hybrid promoter and uses thereof |
CN116327963A (en) | 2016-11-21 | 2023-06-27 | 济世-伊沃泰克生物制品有限公司 | Ophthalmic preparation and application thereof |
KR102578087B1 (en) | 2017-08-17 | 2023-09-18 | 저스트-에보텍 바이오로직스, 아이엔씨. | Method for purifying glycosylated proteins from host cell galectins and other contaminants |
JP7183268B2 (en) | 2017-11-20 | 2022-12-05 | ジャスト-エヴォテック バイオロジックス、インコーポレイテッド | Aflibercept formulation containing lysine salt as tonicity agent and its use |
WO2020168315A1 (en) | 2019-02-15 | 2020-08-20 | Just-Evotec Biologics, Inc. | Automated biomanufacturing systems, facilities, and processes |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
WO2023287707A1 (en) | 2021-07-15 | 2023-01-19 | Just-Evotec Biologics, Inc. | Bidirectional tangential flow filtration (tff) perfusion system |
WO2023154305A2 (en) | 2022-02-10 | 2023-08-17 | Amgen Inc. | Antibody protein product expression constructs for high throughput sequencing |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0123544A2 (en) * | 1983-04-25 | 1984-10-31 | Genentech, Inc. | Process for expressing heterologous protein in yeast, expression vehicles and yeast organisms therefor |
EP0127304A1 (en) * | 1983-04-25 | 1984-12-05 | Genentech, Inc. | Process for producing heterologous protein in yeast, expression vehicle therefor, and yeast transformed therewith |
EP0206783A2 (en) * | 1985-06-20 | 1986-12-30 | The Salk Institute Biotechnology Industrial Associates, Inc. | Expression and secretion of polypeptides from saccharomyces cerevisiae |
EP0220689A2 (en) * | 1985-10-25 | 1987-05-06 | Zymogenetics, Inc. | Method of using bar1 for secreting foreign proteins |
EP0252561A2 (en) * | 1986-07-11 | 1988-01-13 | SCLAVO S.p.A. | Expression and secretion vector in yeasts, useful for preparing heterologous proteins |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4588684A (en) * | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
FR2593518B1 (en) * | 1985-05-02 | 1989-09-08 | Transgene Sa | VECTORS FOR THE EXPRESSION AND SECRETION OF HIRUDIN BY TRANSFORMED YEASTS |
AU6543286A (en) * | 1985-10-25 | 1987-05-19 | Zymogenetics Inc. | Method of using bar1 for secreting foreign proteins |
GB8613388D0 (en) * | 1986-06-03 | 1986-07-09 | Delta Biotechnology Ltd | Induction of galactose regulated gene expression in yeast |
JP2507874B2 (en) * | 1986-11-27 | 1996-06-19 | 工業技術院長 | DNA sequence encoding a secretory signal peptide |
-
1989
- 1989-07-14 JP JP01508293A patent/JP3092811B2/en not_active Expired - Lifetime
- 1989-07-14 WO PCT/GB1989/000816 patent/WO1990001063A1/en active IP Right Grant
- 1989-07-14 DE DE68925893T patent/DE68925893T2/en not_active Expired - Lifetime
- 1989-07-14 AU AU40427/89A patent/AU633020B2/en not_active Expired
- 1989-07-14 EP EP89909015A patent/EP0387319B1/en not_active Expired - Lifetime
- 1989-07-14 KR KR1019900700595A patent/KR100195632B1/en not_active IP Right Cessation
- 1989-07-14 HU HU894572A patent/HU213571B/en unknown
- 1989-07-14 AT AT89909015T patent/ATE135045T1/en not_active IP Right Cessation
- 1989-07-17 CA CA000605832A patent/CA1340547C/en not_active Expired - Fee Related
- 1989-07-18 IL IL9102489A patent/IL91024A/en unknown
- 1989-07-20 IE IE236189A patent/IE62266B1/en not_active IP Right Cessation
- 1989-12-21 GB GB8928849A patent/GB2230268B/en not_active Expired
-
1990
- 1990-03-21 FI FI901428A patent/FI104564B/en active IP Right Grant
- 1990-03-21 DK DK199000729A patent/DK175853B1/en not_active IP Right Cessation
-
1993
- 1993-05-21 US US08/067,243 patent/US5302697A/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0123544A2 (en) * | 1983-04-25 | 1984-10-31 | Genentech, Inc. | Process for expressing heterologous protein in yeast, expression vehicles and yeast organisms therefor |
EP0127304A1 (en) * | 1983-04-25 | 1984-12-05 | Genentech, Inc. | Process for producing heterologous protein in yeast, expression vehicle therefor, and yeast transformed therewith |
EP0206783A2 (en) * | 1985-06-20 | 1986-12-30 | The Salk Institute Biotechnology Industrial Associates, Inc. | Expression and secretion of polypeptides from saccharomyces cerevisiae |
EP0220689A2 (en) * | 1985-10-25 | 1987-05-06 | Zymogenetics, Inc. | Method of using bar1 for secreting foreign proteins |
EP0252561A2 (en) * | 1986-07-11 | 1988-01-13 | SCLAVO S.p.A. | Expression and secretion vector in yeasts, useful for preparing heterologous proteins |
Non-Patent Citations (1)
Title |
---|
DIALOG INFORMATION SERVICES, File 351, World Patent Index 81-89, Dialog Accession No. 88-195319/28, AGENCY OF IND. SCI. TECH., "DNA Sequence Coding Secretory Signal Peptide - Secretes Protein when DNA Sequence is Integrated Between Promoter and Exotix Gene in Yeast Host"; & JP,A,63 133 986, (06-06-88), 8828 (Basic). * |
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0366400A3 (en) * | 1988-10-26 | 1990-08-01 | Tonen Corporation | Dna encoding human serum albumin a (hsa), plasmids and hosts containing such dna, and the production of hsa |
US5759802A (en) * | 1988-10-26 | 1998-06-02 | Tonen Corporation | Production of human serum alubumin A |
EP0366400A2 (en) * | 1988-10-26 | 1990-05-02 | Tonen Corporation | DNA encoding human serum albumin a (HSA), plasmids and hosts containing such DNA, and the production of HSA |
WO1992011378A1 (en) * | 1990-12-19 | 1992-07-09 | Novo Nordisk A/S | A method of constructing synthetic leader sequences |
US5521086A (en) * | 1993-09-16 | 1996-05-28 | Cephalon, Inc. | Secretion sequence for the production of a heterologous protein in yeast |
US5919654A (en) * | 1995-02-03 | 1999-07-06 | Asahi Glass Company Ltd. | Secretion signal gene and expression vector containing it |
EP1681304A2 (en) | 1995-12-30 | 2006-07-19 | Delta Biotechnology Limited | Recombinant fusion proteins of growth hormone and serum albumin |
US7045318B2 (en) * | 1995-12-30 | 2006-05-16 | Delta Biotechnology Limited | Recombinant fusion proteins to growth hormone and serum albumin |
US8642542B2 (en) | 1995-12-30 | 2014-02-04 | Novozymes Biopharma Dk A/S | Recombinant fusion proteins to growth hormone and serum albumin |
US6867231B1 (en) | 1997-06-14 | 2005-03-15 | Enzacta R & D Limited | Therapeutic systems |
US7138122B2 (en) | 1997-06-14 | 2006-11-21 | Enzacta R & D Limited | Therapeutic systems |
EP2048234A1 (en) | 1999-01-30 | 2009-04-15 | Novozymes Biopharma UK Limited | Chromatographic method for purification of albumin |
EP2272961A1 (en) | 1999-01-30 | 2011-01-12 | Novozymes Biopharma DK A/S | Process for producing recombinant albumin with reduced mannosylation |
EP2267026A1 (en) | 2000-04-12 | 2010-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2236152A1 (en) | 2000-04-12 | 2010-10-06 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2357008A1 (en) | 2000-04-12 | 2011-08-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2311872A1 (en) | 2000-04-12 | 2011-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2298355A2 (en) | 2000-04-12 | 2011-03-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2295456A1 (en) | 2000-04-12 | 2011-03-16 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9821039B2 (en) | 2000-04-12 | 2017-11-21 | Albumedix A/S | Albumin fusion proteins |
US9849162B2 (en) | 2000-04-12 | 2017-12-26 | Albumedix A/S | Treatment with factor VII-albumin fusion protein |
EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2216409A1 (en) | 2000-04-12 | 2010-08-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7847079B2 (en) | 2001-12-21 | 2010-12-07 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2277888A2 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Fusion proteins of albumin and erythropoietin |
US8252739B2 (en) | 2001-12-21 | 2012-08-28 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2990417A1 (en) | 2001-12-21 | 2016-03-02 | Human Genome Sciences, Inc. | Albumin insulin fusion protein |
EP2261250A1 (en) | 2001-12-21 | 2010-12-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8071539B2 (en) | 2001-12-21 | 2011-12-06 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8513189B2 (en) | 2001-12-21 | 2013-08-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2277889A2 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
US7799759B2 (en) | 2001-12-21 | 2010-09-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9296809B2 (en) | 2001-12-21 | 2016-03-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1997829A1 (en) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8211439B2 (en) | 2001-12-21 | 2012-07-03 | Human Genome Sciences, Inc. | Albumin fusion proteins comprising insulin polypeptides |
US9221896B2 (en) | 2001-12-21 | 2015-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8012464B2 (en) | 2001-12-21 | 2011-09-06 | Human Genome Sciences, Inc. | G-CSF-albumin fusion proteins |
EP2090589A1 (en) | 2002-02-07 | 2009-08-19 | Dyax Corp. | Albumin-fused Kunitz domain peptides |
WO2004009819A3 (en) * | 2002-07-23 | 2004-03-25 | Delta Biotechnology Ltd | Polypeptides with a signal sequence comprising an fivsi motif and olynucleotides encoding therefor |
EP2390333A1 (en) | 2002-07-23 | 2011-11-30 | Novozymes Biopharma DK A/S | Polypeptides comprising a modified human serum albumin secretion pre-sequence with improved secretion yield |
US9133265B2 (en) | 2002-07-23 | 2015-09-15 | Novozymes Biopharma Dk A/S | Gene and polypeptide sequences |
GB2406571A (en) * | 2002-07-23 | 2005-04-06 | Delta Biotechnology Ltd | Polypeptides with a signal sequence comprising an fivsi motif and olynucleotides encoding therefor |
US8258102B2 (en) | 2002-07-23 | 2012-09-04 | Novozymes Biopharma Dk A/S | Gene and polypeptide sequences |
WO2004009819A2 (en) * | 2002-07-23 | 2004-01-29 | Delta Biotechnology Limited | Polypeptides with a signal sequence comprising an fivsi motif and olynucleotides encoding therefor |
GB2406571B (en) * | 2002-07-23 | 2007-02-21 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
US9057061B2 (en) | 2003-12-23 | 2015-06-16 | Novozymes Biopharma Dk A/S | Gene expression technique |
EP2048236A1 (en) | 2003-12-23 | 2009-04-15 | Novozymes Biopharma DK A/S | Gene expression technique |
US8969064B2 (en) | 2003-12-23 | 2015-03-03 | Novozymes Biopharma Dk A/S | Gene expression technique |
US8252551B2 (en) | 2003-12-23 | 2012-08-28 | Novozymes Biopharma Dk A/S | 2-micron family plasmid and use thereof |
US8420087B2 (en) | 2004-01-05 | 2013-04-16 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
EP2330200A2 (en) | 2004-12-23 | 2011-06-08 | Novozymes Biopharma DK A/S | Gene expression technique |
WO2006067511A1 (en) | 2004-12-23 | 2006-06-29 | Novozymes Delta Limited | Gene expression technique |
US8765915B2 (en) | 2006-02-06 | 2014-07-01 | Csl Behring Gmbh | Modified coagulation factor VIIa with extended half-life |
US9505823B2 (en) | 2006-08-07 | 2016-11-29 | TEV A Biopharmaceuticals USA, Inc. | Albumin-insulin fusion proteins |
EP2604623A2 (en) | 2007-08-08 | 2013-06-19 | Novozymes Biopharma DK A/S | Transferrin variants and conjugates |
WO2009019314A1 (en) | 2007-08-08 | 2009-02-12 | Novozymes A/S | Transferrin variants and conjugates |
EP2594583A1 (en) | 2007-08-08 | 2013-05-22 | Novozymes Biopharma DK A/S | Transferrin variants and conugates |
EP2617733A1 (en) | 2009-02-06 | 2013-07-24 | Novozymes Biopharma DK A/S | Purification process |
WO2010089385A1 (en) | 2009-02-06 | 2010-08-12 | Novozymes Biopharma Dk A/S | Purification process |
EP3243835A1 (en) | 2009-02-11 | 2017-11-15 | Albumedix A/S | Albumin variants and conjugates |
WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
US10711051B2 (en) | 2011-03-03 | 2020-07-14 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
US10155803B2 (en) | 2011-03-03 | 2018-12-18 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
US9499605B2 (en) | 2011-03-03 | 2016-11-22 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
WO2014012082A2 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
US9388231B2 (en) | 2012-07-13 | 2016-07-12 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
US10358479B2 (en) | 2012-07-13 | 2019-07-23 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
US11248037B2 (en) | 2012-07-13 | 2022-02-15 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
WO2014182970A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
WO2016086320A1 (en) | 2014-12-05 | 2016-06-09 | UNIVERSITé LAVAL | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
US10023618B2 (en) | 2015-12-22 | 2018-07-17 | Albumedix A/S | Protein expression strains |
WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
WO2018234349A1 (en) | 2017-06-20 | 2018-12-27 | Albumedix Ltd | Improved protein expression strains |
EP4026908A1 (en) | 2017-06-20 | 2022-07-13 | Albumedix Ltd | Improved protein expression strains |
US11130979B2 (en) | 2017-06-20 | 2021-09-28 | Albumedix Ltd | Protein expression strains |
US11396670B2 (en) | 2017-06-20 | 2022-07-26 | Albumedix Limited | Protein expression strains |
Also Published As
Publication number | Publication date |
---|---|
KR100195632B1 (en) | 1999-06-15 |
DK175853B1 (en) | 2005-04-04 |
GB2230268B (en) | 1992-01-29 |
JP3092811B2 (en) | 2000-09-25 |
IE62266B1 (en) | 1995-01-11 |
ATE135045T1 (en) | 1996-03-15 |
JPH03500370A (en) | 1991-01-31 |
DE68925893T2 (en) | 1996-08-08 |
AU633020B2 (en) | 1993-01-21 |
US5302697A (en) | 1994-04-12 |
GB8928849D0 (en) | 1990-07-18 |
GB2230268A (en) | 1990-10-17 |
HU894572D0 (en) | 1991-05-28 |
EP0387319A1 (en) | 1990-09-19 |
KR920700288A (en) | 1992-02-19 |
DE68925893D1 (en) | 1996-04-11 |
FI104564B (en) | 2000-02-29 |
DK72990A (en) | 1990-03-21 |
IL91024A0 (en) | 1990-02-09 |
IL91024A (en) | 1995-08-31 |
HU213571B (en) | 1997-08-28 |
FI901428A0 (en) | 1990-03-21 |
DK72990D0 (en) | 1990-03-21 |
IE892361L (en) | 1990-01-23 |
CA1340547C (en) | 1999-05-18 |
EP0387319B1 (en) | 1996-03-06 |
AU4042789A (en) | 1990-02-19 |
HUT57829A (en) | 1991-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5302697A (en) | Peptide and DNA sequences | |
AU660161B2 (en) | A method of constructing synthetic leader sequences | |
EP0792367B1 (en) | A dna construct encoding the yap3 signal peptide | |
JP3676369B2 (en) | Synthetic leader peptide sequences | |
JP2791418B2 (en) | Method for producing heterologous protein, recombinant DNA, transformant | |
EP0361991A2 (en) | Method for the microbiological preparation of human serum albumin and other heterologous proteins from a yeast | |
JPS63501614A (en) | How to use BAR1 to secrete foreign proteins | |
IL114160A (en) | Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast | |
HU211600A9 (en) | Yeast expressing system | |
AU667852B2 (en) | Novel DNA molecules and hosts | |
Achstetter et al. | A new signal peptide useful for secretion of heterologous proteins from yeast and its application for synthetis of hirudin | |
EP1015612B1 (en) | Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae | |
EP0424117A1 (en) | Yeast promoter | |
US5521093A (en) | Yeast vector coding for heterologous gene fusions linked via KEX2 cleavage site and coding for truncated KEX2 genes | |
JP4180112B2 (en) | Vector for expression of N-terminally extended protein in yeast cells | |
Goodey et al. | Expression and secretion of foreign polypeptides in yeast |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1989909015 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI GB HU JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 901428 Country of ref document: FI Ref document number: 1019900700595 Country of ref document: KR |
|
WR | Later publication of a revised version of an international search report | ||
WWP | Wipo information: published in national office |
Ref document number: 1989909015 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1989909015 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 901428 Country of ref document: FI |